Put the money that went to Bird here: On June
Post# of 36537
(Total Views: 506)
Posted On: 11/13/2020 9:31:09 PM
Put the money that went to Bird here:
On June 2, 2020, the Company entered into a Laboratory Services Agreement and Statement of Work Agreement with Cellular Technology Limited (“CTL”). The agreement calls for CTL to provide certain laboratory testing and analysis. These services provided by CTL to Generex are part of the development of a potential vaccine for COVID-19 based upon NGIO Ii-Key vaccine technology. NGIO is a majority owned subsidiary of Generex. Generex and NGIO will own the intellectual property generated by CTL’s work.
Pursuant to this agreement, Generex will pay to CTL a fee for work plan completion of $939,478. During the fiscal year ended July 31, 2020, $4,697 has been incurred under this agreement.”
There’s nothing more important than funding this vaccine. No one is interested at this point in screws for flat feet from a couple companies overly reliant on the Veneto legacy company. Arizona and that hso or a new mso could be better, but not now. Fund success first. Vaccines only in 2020.
On June 2, 2020, the Company entered into a Laboratory Services Agreement and Statement of Work Agreement with Cellular Technology Limited (“CTL”). The agreement calls for CTL to provide certain laboratory testing and analysis. These services provided by CTL to Generex are part of the development of a potential vaccine for COVID-19 based upon NGIO Ii-Key vaccine technology. NGIO is a majority owned subsidiary of Generex. Generex and NGIO will own the intellectual property generated by CTL’s work.
Pursuant to this agreement, Generex will pay to CTL a fee for work plan completion of $939,478. During the fiscal year ended July 31, 2020, $4,697 has been incurred under this agreement.”
There’s nothing more important than funding this vaccine. No one is interested at this point in screws for flat feet from a couple companies overly reliant on the Veneto legacy company. Arizona and that hso or a new mso could be better, but not now. Fund success first. Vaccines only in 2020.
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼